Adverse effects in the management of breast cancer – recent studies
DOI:
https://doi.org/10.12775/JEHS.2023.37.01.001Keywords
Breast cancer, breast cancer treatment, radiotherapy, immunotherapy, toxicity, chemotherapyAbstract
Introduction and purpose
Breast cancer (BC) management includes local therapies surgery, radiotherapy and systemic – hormonotherapy, chemotherapy, targeted and immunotherapy. However, some adverse events of these treatment strategies limit their wide administration in BC therapy. The aim of the study was to present adverse effects in the management of BC, prevention and treatment of them.
State of the knowledge
Surgery of the breast leads to lymphedema, pain, and anatomical changes. The most characteristic adverse event of radiotherapy is radiation dermatitis which is more probable among obese, older patients, females, and smokers. Other side effects are pneumonia, cardiac and pulmonary injury. Chemotherapeutics lead to complications such as anthracyclines-induced cardiotoxicity. As a consequence of endocrine therapy, patients are affected by vasomotor, musculoskeletal, and vulvovaginal symptoms. Immune checkpoint inhibitors may cause immune-related adverse events (irAEs), which are usually mild. When severe irAEs occur, immunosuppressive drugs are used. Depending on stage, toxicities of the therapies can lead to interrupting the treatment of BC. Moreover, drug resistance is an important therapeutic obstacle in BC treatment.
Conclusion
The application of a diversity of drugs in the treatment of breast cancer is associated with adverse effects which limit its efficacy. It is vital to develop novel, targeted therapeutic methods to optimize outcomes of patients. Given the adverse effects of breast cancer therapies and drug resistance, it is vital to develop novel, targeted therapeutic methods.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
2. Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015 Nov;24 Suppl 2(0 2):S149-53. doi: 10.1016/j.breast.2015.07.035. Epub 2015 Aug 20. PMID: 26299406; PMCID: PMC4743500.
Cedolini C, Bertozzi S, Londero AP, Bernardi S, Seriau L, Concina S, Cattin F, Risaliti A. Type of breast cancer diagnosis, screening, and survival. Clin Breast Cancer. 2014 Aug;14(4):235-40. doi: 10.1016/j.clbc.2014.02.004. Epub 2014 Feb 20. PMID: 24703317.
Thalji SZ, Cortina CS, Guo MS, Kong AL. Postoperative Complications from Breast and Axillary Surgery. Surg Clin North Am. 2023 Feb;103(1):121-139. doi: 10.1016/j.suc.2022.08.007. Epub 2022 Oct 18. PMID: 36410345.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848. PMID: 24656685; PMCID: PMC5015598.
Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019 Sep;177(2):237-250. doi: 10.1007/s10549-019-05303-y. Epub 2019 Jun 5. PMID: 31165940; PMCID: PMC6661020.
Czajka ML, Pfeifer C. Breast Cancer Surgery. [Updated 2023 Feb 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:https://www.ncbi.nlm.nih.gov/books/NBK553076/
Drăgănescu M, Carmocan C. Hormone Therapy in Breast Cancer. Chirurgia (Bucur). 2017 Jul-Aug;112(4):413-417. doi: 10.21614/chirurgia.112.4.413. PMID: 28862117.
Provenzano E. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. Acta Med Acad. 2021 Apr;50(1):88-109. doi: 10.5644/ama2006-124.328. PMID: 34075766.
Burguin A, Diorio C, Durocher F. Breast Cancer Treatments: Updates and New Challenges. J Pers Med. 2021 Aug 19;11(8):808. doi: 10.3390/jpm11080808. PMID: 34442452; PMCID: PMC8399130.
Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7(1):3-23. doi: 10.2174/2211738507666190122111224. PMID: 30666921; PMCID: PMC6691849.
Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, Opatrilova R, Kruzliak P, Stefanicka P, Büsselberg D. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomed Pharmacother. 2018 May;101:458-477. doi: 10.1016/j.biopha.2018.02.108. Epub 2018 Mar 22. PMID: 29501768.
Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018 Feb 1;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. Epub 2017 Aug 11. PMID: 28801472; PMCID: PMC5796849.
Henriques B, Mendes F, Martins D. Immunotherapy in Breast Cancer: When, How, and What Challenges? Biomedicines. 2021 Nov 14;9(11):1687. doi: 10.3390/biomedicines9111687. PMID: 34829916; PMCID: PMC8616011.
Lovelace DL, McDaniel LR, Golden D. Long-Term Effects of Breast Cancer Surgery, Treatment, and Survivor Care. J Midwifery Womens Health. 2019 Nov;64(6):713-724. doi: 10.1111/jmwh.13012. Epub 2019 Jul 19. PMID: 31322834.
Ebner F, Friedl TWP, de Gregorio A, Lato K, Bekes I, Janni W, de Gregorio N. Seroma in breast surgery: all the surgeons fault? Arch Gynecol Obstet. 2018 Nov;298(5):951-959. doi: 10.1007/s00404-018-4880-8. Epub 2018 Sep 8. PMID: 30196358.
Lotfy W, Mohamed O, Elhady L, Abuojaylah M. An Overview of Post Mastectomy Seroma and Treatment Options: Review Article. The Egyptian Journal of Hospital Medicine. 2022 Jul;88(1), 2568-2570. doi: 10.21608/ejhm.2022.239192
Sakkary MA. The value of mastectomy flap fixation in reducing fluid drainage and seroma formation in breast cancer patients. World J Surg Oncol. 2012 Jan 11;10:8. doi: 10.1186/1477-7819-10-8. PMID: 22236813; PMCID: PMC3279306.
Srivastava V, Basu S, Shukla VK. Seroma formation after breast cancer surgery: what we have learned in the last two decades. J Breast Cancer. 2012 Dec;15(4):373-80. doi: 10.4048/jbc.2012.15.4.373. Epub 2012 Dec 31. PMID: 23346164; PMCID: PMC3542843.
Turner EJ, Benson JR, Winters ZE. Techniques in the prevention and management of seromas after breast surgery. Future Oncol. 2014 May;10(6):1049-63. doi: 10.2217/fon.13.257. PMID: 24941989.
van Bastelaar J, van Roozendaal L, Granzier R, Beets G, Vissers Y. A systematic review of flap fixation techniques in reducing seroma formation and its sequelae after mastectomy. Breast Cancer Res Treat. 2018 Jan;167(2):409-416. doi: 10.1007/s10549-017-4540-x. Epub 2017 Oct 16. PMID: 29039118.
Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: A meta-analysis. Eur J Surg Oncol. 2015 Aug;41(8):958-66. doi: 10.1016/j.ejso.2015.05.007. Epub 2015 Jun 2. PMID: 26054706.
Palubicka A, Jaworski R, Wekwejt M, Swieczko-Zurek B, Pikula M, Jaskiewicz J, Zielinski J. Surgical Site Infection after Breast Surgery: A Retrospective Analysis of 5-Year Postoperative Data from a Single Center in Poland. Medicina (Kaunas). 2019 Aug 21;55(9):512. doi: 10.3390/medicina55090512. PMID: 31438594; PMCID: PMC6780406.
Al-Hilli Z, Wilkerson A. Breast Surgery: Management of Postoperative Complications Following Operations for Breast Cancer. Surg Clin North Am. 2021 Oct;101(5):845-863. doi: 10.1016/j.suc.2021.06.014. Epub 2021 Aug 7. PMID: 34537147.
Londero AP, Bertozzi S, Cedolini C, Neri S, Bulfoni M, Orsaria M, Mariuzzi L, Uzzau A, Risaliti A, Barillari G. Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery. Cancers (Basel). 2022 Feb 16;14(4):988. doi: 10.3390/cancers14040988. PMID: 35205736; PMCID: PMC8870485.
Castaldi M, George G, Stoller C, Parsikia A, McNelis J. Independent Predictors of Venous Thromboembolism in Patients Undergoing Reconstructive Breast Cancer Surgery. Plast Surg (Oakv). 2021 Aug;29(3):160-168. doi: 10.1177/2292550320967397. Epub 2020 Oct 28. PMID: 34568231; PMCID: PMC8436332.
Nicola A, Crowley M, See M. A novel algorithm to reduce VTE in peri-operative patients on tamoxifen. Breast. 2021 Aug;58:88-92. doi: 10.1016/j.breast.2021.04.009. Epub 2021 May 6. PMID: 33989964; PMCID: PMC8135035.
Saldanha IJ, Cao W, Broyles JM, et al. Breast Reconstruction After Mastectomy: A Systematic Review and Meta-Analysis [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Jul. (Comparative Effectiveness Review, No. 245.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK572812/ doi: 10.23970/AHRQEPCCER245
Feng H, Wang H, Xu L, Ren Y, Ni Q, Yang Z, Ma S, Deng Q, Chen X, Xia B, Kuang Y, Li X. Prediction of radiation-induced acute skin toxicity in breast cancer patients using data encapsulation screening and dose-gradient-based multi-region radiomics technique: A multicenter study. Front Oncol. 2022 Nov 10;12:1017435. doi: 10.3389/fonc.2022.1017435. PMID: 36439515; PMCID: PMC9686850.
Yu HB, Han BJ, Cao HJ. Prevention of Radiodermatitis With Topical Chinese Herbal Medicine: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022 Jun 22;13:819733. doi: 10.3389/fphar.2022.819733. PMID: 35814240; PMCID: PMC9257048.
Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001 Jun;59(3):237-45. doi: 10.1016/s0167-8140(01)00328-0. PMID: 11369064.
Bhangoo RS, Cheng TW, Petersen MM, Thorpe CS, DeWees TA, Anderson JD, Vargas CE, Patel SH, Halyard MY, Schild SE, Wong WW. Radiation recall dermatitis: A review of the literature. Semin Oncol. 2022 Apr;49(2):152-159. doi: 10.1053/j.seminoncol.2022.04.001. Epub 2022 Apr 29. PMID: 35585004.
Vieira LAC, Menêses AG, Bontempo PSM, Simino GPR, Ferreira EB, Guerra ENDS, Reis PEDD. Incidence of radiodermatitis in breast cancer patients during hypofractionated radiotherapy. Rev Esc Enferm USP. 2022 Dec 5;56:e20220173. doi: 10.1590/1980-220X-REEUSP-2022-0173en. PMID: 36469486; PMCID: PMC10081640.
Ma X, Jin Z, Li G, Yang W. Classification of chronic radiation-induced ulcers in the chest wall after surgery in breast cancers. Radiat Oncol. 2017 Aug 15;12(1):135. doi: 10.1186/s13014-017-0876-y. PMID: 28810878; PMCID: PMC5558728.
Shavit E, Alavi A. Get It Off Your Chest: A Narrative Review of Breast Ulcers. Adv Skin Wound Care. 2022 Jun 1;35(6):306-313. doi: 10.1097/01.ASW.0000826864.20824.b5. PMID: 35703852.
Liu L, Yang Y, Guo Q, Ren B, Peng Q, Zou L, Zhu Y, Tian Y. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020 Jan 17;15(1):17. doi: 10.1186/s13014-020-1463-1. PMID: 31952507; PMCID: PMC6969477.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340. PMID: 26200977; PMCID: PMC4556358.
Taylor CW, Kirby AM. Cardiac Side-effects From Breast Cancer Radiotherapy. Clin Oncol (R Coll Radiol). 2015 Nov;27(11):621-9. doi: 10.1016/j.clon.2015.06.007. Epub 2015 Jun 28. PMID: 26133462.
Nomura M, Morita Y, Kakiuchi A, Ishida K, Iizuka M, Yagi Y, Jobu K, Miyamura M. The association between chemotherapy-induced febrile neutropenia and breast cancer subtype in Japanese patients. Int J Clin Pharm. 2020 Feb;42(1):7-10. doi: 10.1007/s11096-019-00952-x. Epub 2019 Dec 21. PMID: 31865592.
de Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer. 2002 Feb 15;94(4):895-901. doi: 10.1002/cncr.20335.abs. PMID: 11920456.
Hernandez-Aya LF, Ma CX. Chemotherapy principles of managing stage IV breast cancer in the United States. Chin Clin Oncol. 2016 Jun;5(3):42. doi: 10.21037/cco.2016.04.01. Epub 2016 Apr 14. PMID: 27164855.
Mu Q, Wang H, Zhang M. Nanoparticles for imaging and treatment of metastatic breast cancer. Expert Opin Drug Deliv. 2017 Jan;14(1):123-136. doi: 10.1080/17425247.2016.1208650. Epub 2016 Jul 19. PMID: 27401941; PMCID: PMC5835024.
Hanna K, Mayden K. Chemotherapy Treatment Considerations in Metastatic Breast Cancer. J Adv Pract Oncol. 2021 Mar;12(Suppl 2):6-12. doi: 10.6004/jadpro.2021.12.2.11. Epub 2021 Mar 1. PMID: 34113474; PMCID: PMC8020942.
Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J Cancer. 2015 Mar;51(4):437-450. doi: 10.1016/j.ejca.2014.12.017. Epub 2015 Jan 23. PMID: 25623439.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645. PMID: 28564564.
Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2. PMID: 34037241; PMCID: PMC8150746.
Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020 May 13;14(1):442. doi: 10.4081/oncol.2020.442. PMID: 32431787; PMCID: PMC7232019.
Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D, Brodowicz T. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer. 2016 Jan 19;114(2):163-70. doi: 10.1038/bjc.2015.419. Epub 2015 Dec 10. PMID: 26657657; PMCID: PMC4815806.
Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006 Mar 1;24(7):1045-51. doi: 10.1200/JCO.2005.03.3969. Epub 2006 Feb 13. PMID: 16476708.
Prihantono, Faruk M. Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it? Ann Med Surg (Lond). 2021 Sep 4;70:102793. doi: 10.1016/j.amsu.2021.102793. PMID: 34691411; PMCID: PMC8519754.
Yang F, He Q, Dai X, Zhang X, Song D. The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. Front Pharmacol. 2023 Feb 22;14:1143102. doi: 10.3389/fphar.2023.1143102. PMID: 36909177; PMCID: PMC9992554.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101. PMID: 11248153.
Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018 Nov;18(11):1101-1112. doi: 10.1080/14737140.2018.1520096. Epub 2018 Sep 21. PMID: 30188738.
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP; WHEL Study Group. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008 Apr;108(3):421-6. doi: 10.1007/s10549-007-9612-x. Epub 2007 May 31. PMID: 17541741; PMCID: PMC2575100.
Lee M, Piao J, Jeon MJ. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Yonsei Med J. 2020 Apr;61(4):317-322. doi: 10.3349/ymj.2020.61.4.317. PMID: 32233174; PMCID: PMC7105402.
Yu Q, Xu Y, Yu E, Zheng Z. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis. J Clin Pharm Ther. 2022 May;47(5):575-587. doi: 10.1111/jcpt.13598. Epub 2022 Jan 4. PMID: 34984740.
Khosrow-Khavar F, Filion KB, Al-Qurashi S, Torabi N, Bouganim N, Suissa S, Azoulay L. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017 Mar 1;28(3):487-496. doi: 10.1093/annonc/mdw673. PMID: 27998966; PMCID: PMC5834146.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26. PMID: 30475668; PMCID: PMC6325353.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. PMID: 29863451; PMCID: PMC6193457.
de Araujo Sensever F, Jardim LC, Ferrazzo KL, Skupien JA, Antoniazzi RP. Association between tamoxifen and tooth loss in women with breast cancer. Support Care Cancer. 2022 Oct;30(10):8193-8199. doi: 10.1007/s00520-022-07271-4. Epub 2022 Jul 7. PMID: 35796887.
Jackson C, Finikarides L, Freeman ALJ. The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis. PLoS One. 2022 Dec 1;17(12):e0275321. doi: 10.1371/journal.pone.0275321. PMID: 36454979; PMCID: PMC9714930.
Meunier L, Larrey D. Chemotherapy-associated steatohepatitis. Ann Hepatol. 2020 Nov-Dec;19(6):597-601. doi: 10.1016/j.aohep.2019.11.012. Epub 2020 Jan 30. PMID: 32061473.
Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. Andrology. 2016 Sep;4(5):776-88. doi: 10.1111/andr.12197. Epub 2016 May 6. PMID: 27152880.
Balibegloo M, Nejadghaderi SA, Sadeghalvad M, Soleymanitabar A, Salehi Nezamabadi S, Saghazadeh A, Rezaei N. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis. Int Immunopharmacol. 2021 Jul;96:107796. doi: 10.1016/j.intimp.2021.107796. Epub 2021 May 25. PMID: 34162158.
Majd N, de Groot J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin Pharmacother. 2019 Sep;20(13):1609-1624. doi: 10.1080/14656566.2019.1621840. Epub 2019 Jul 2. PMID: 31264484.
Yang Y, Wu Q, Chen L, Qian K, Xu X. Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report. Ann Transl Med. 2022 Apr;10(7):424. doi: 10.21037/atm-22-1284. PMID: 35530956; PMCID: PMC9073793.
Zhang Y, Wang J, Hu T, Wang H, Long M, Liang B. Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Life (Basel). 2022 Nov 28;12(12):1990. doi: 10.3390/life12121990. PMID: 36556355; PMCID: PMC9787874.
Sharmni Vishnu K, Win TT, Aye SN, Basavaraj AK. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. BMC Cancer. 2022 Nov 5;22(1):1139. doi: 10.1186/s12885-022-10225-y. PMID: 36335316; PMCID: PMC9637314.
Common Terminology Criteria for Adverse Events (CTCAE), Protocol Development, CTEP Available from: https://wwwctepcancergov/protocolDevelopment/electronic_applications/ctchtm#ctc_50, Accessed 20th Dec 2018
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(36):4073–126.
Nunes Filho P, Albuquerque C, Pilon Capella M, Debiasi M. Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review. Oncol Ther. 2023 Mar 14. doi: 10.1007/s40487-023-00224-9. Epub ahead of print. PMID: 36917399.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marcela Maksymowicz, Piotr Machowiec, Anna Korzeniowska, Natalia Baran, Adriana Bielak, Aleksandra Nowak, Łucja Cywka, Weronika Szwed, Alicja Nowak, Klaudia Bogusz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 419
Number of citations: 0